103 Alliance UniChem Plc 42 ACQUISITIONS CONTINUED Purchase of businesses continued Retail Book Provisional value at Fair value fair value at acquisition adjustments acquisition Assets acquired at book and provisional fair value million million million Intangible assets retail pharmacy licences 24.7 69.2 93.9 Property, plant and equipment 6.7 0.2 6.5 Inventories 11.2 0.5 10.7 Trade and other receivables 9.2 0.2 9.4 Borrowings bank overdrafts 2.5 2.5 bank loans 2.5 2.5 Trade and other payables 10.7 10.7 Current corporate tax liabilities 3.3 0.1 3.4 Deferred tax liabilities 20.6 20.6 Net assets acquired 32.8 48.0 80.8 Consideration paid million Cash 117.3 Deferred consideration movement 0.3 117.0 Purchased goodwill 36.2 Retail acquisitions comprised the acquisition of 83 pharmacies in the UK, Norway and The Netherlands.
43 DISPOSALS Disposal of businesses During the year the Group disposed of 51% of its interest in Alliance UniChem Farmacutica A. G. its entire interest in Elvetec in France and a number of other minor interests.
The proceeds received for these transactions were 32.5 million.
Within the balance sheets of the businesses disposed were net overdrafts of 66.2 million.
In addition, the Group received deferred consideration of 12.0 million arising from the disposal of non-core UK businesses in 2004.
Disposal of investments in associates As described in note 42, during the year the Group restructured its relationship with Galenica A. G..
The transaction was settled on a net basis and resulted in a net cash inflow to the Group of 15.7 million.
This comprised 8.6 million of net proceeds, 41.4 million of associate loans being repaid and, in respect of the acquired companies, 2.0 million of net cash and 36.3 million of borrowings were held in the acquired balance sheets.
In addition, the Group disposed of a minor associated undertaking for disposal proceeds of 0.1 million.
Disposal of available-for-sale investments During the first half of the year, the Group disposed of its investment in Sanacorp Pharmahandel A. G.. 44 SHARE-BASED PAYMENTS The Group issues equity settled, share-based payments to certain employees.
Equity settled share-based payments are measured at fair value at the date of grant.
The fair value determined at the grant date of the equity settled, share-based payments is expensed on a straight-line basis over the vesting period, based on the Groups estimate of shares that will eventually vest.
Fair value is measured by use of an actuarial binomial model.
The model includes adjustments, based on managements best estimate, for the effects of exercise restrictions, behavioural considerations and expected dividend payments.
The option life is derived by the model based on these assumptions and the other assumptions identified below.
The total expense included within profit from operations in respect of share-based payments was 5.3 million 2004 2.2 million.
